Hepatitis C is a global public health problem, and a major cause of chronic hepatitis. The virus can cause cirrhosis, liver failure and primary liver cancer. Combination therapy is effective in 50-60 per cent of patients with chronic infection. Prevention initiatives should target high-risk groups, such as injecting drug users.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Incidence and Risk Factors for Varicella-Zoster Virus-Associated Central Nervous System Infections: A Nationwide Swedish Retrospective Case-Control Study.
J Med Virol
February 2025
Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
The determinants of varicella-zoster virus (VZV)-associated central nervous system (CNS) infection have not been fully elucidated. This study aimed to investigate the incidence and risk factors, including immunosuppression, for different manifestations of VZV-associated CNS infection. Patient registers were used to include adults diagnosed with VZV-associated CNS infections between 2010 and 2019 in Sweden.
View Article and Find Full Text PDFAssociation between blood test indicators and atrial fibrillation in elderly patients aged 65 and above in the Central Jiangsu region: a cross-sectional study.
BMC Cardiovasc Disord
January 2025
Department of Cardiology, Northern Jiangsu People's Hospital, Nantong West Road No. 98, Yangzhou, Jiangsu, 225001, China.
Objectives: The aim of this study was to explore the correlation between blood test indicators and Atrial Fibrillation (AF) in Individuals Aged 65 and Older in Yangzhou, Jiangsu.
Methods: From January 1, 2019, to August 31, 2023, an epidemiological cross-sectional survey was conducted among the elderly population undergoing health check-ups at Northern Jiangsu People's Hospital in Jiangsu Province. Patients diagnosed with AF after a 12-lead electrocardiogram were included in the case group, and non-AF individuals matched by age and gender in a 1:4 frequency ratio were included in the control group.
Effect of enhanced recovery after surgery on older patients undergoing transvaginal pelvic floor reconstruction surgery: a randomised controlled trial.
BMC Med
January 2025
Department of Gynaecology and Obstetrics, Women and Children's Hospital of Chongqing Medical University (Chongqing Health Center for Women and Children), Chongqing, China.
Background: Prospective trial evidence is lacking regarding the application of enhanced recovery after surgery (ERAS) in transvaginal pelvic floor reconstruction surgery among older patients. Our study aimed to investigate whether implementing the ERAS protocol could enhance post-operative recovery in this patient population.
Methods: Older patients undergoing elective transvaginal pelvic floor reconstruction surgery were randomly assigned to either the ERAS group or the conventional group.
Evaluating the differences in healthy lifestyle behaviors between Chinese urban and rural residency after the termination of social distancing: analysis based on propensity score matching.
BMC Public Health
January 2025
Henan Medical Communication and Project Forward Center, No. 6, Xueli Road, Zhengdong New District, Zhengzhou, 450000, Henan, China.
Background: During the COVID-19 pandemic, the social distancing has significantly affected the healthy lifestyle behaviors of residents. China ended social distancing on January 8, 2023, and the healthy lifestyle behaviors of residents after this time are unclear. The goal of this study was to evaluate the differences in healthy lifestyle behaviors between Chinese urban and rural residency after the termination of social distancing.
View Article and Find Full Text PDFRationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study).
BMC Cancer
January 2025
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2-3 years, depending on risk factors such as previous remission duration. In recent years, growing evidence has suggested that allogeneic stem cell transplantation could be a promising treatment option for patients with relapsed or progressed multiple myeloma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!